Conclusion of a significant agreement
The Management Board of Selvita S.A. with its registered office in Krakow (“Issuer”) hereby informs that on June 30, 2021, the Issuer’s affiliated company – Selvita Inc. (“Company”) concluded an agreement with the University of California San Francisco (“UCSF”) with a total value of $ 4,183,000 (PLN 15,910,801 converted at the rate of USD 1 = PLN 3.8035) (“Agreement”). The Agreement extends the current collaboration between the parties in time and scope. The Issuer has informed about it in its current stock report number 15/2019, dated June 24, 2019.
The services under the Agreement will be executed throughout next 36 months, starting from July 1, 2021. The scope of the services which will be performed in support of clients’ research programs in the area of drug discovery include: synthesis, purification, structure determination and purity analysis of small molecules for the treatment of neurodegenerative diseases.
The terms of the Agreement do not differ from those commonly used for this type of contracts.
The Issuer’s Management Board considers the conclusion of the agreement as significant due to its value and the fact of the extension of the collaboration with one of the important clients of the Company and the importance of this collaboration for the development of the Issuer’s future activities.
Legal basis: Art. 17 par. 1 of MAR
Representatives of the Company:
- Bogusław Sieczkowski – President of the Management Board
- Miłosz Gruca – Vice President of the Management Board